Skip to content
Tablet Allopathic

Calcent 100 mg tablet

Generic: Acalabrutinib

Company: Incepta Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength100 mg
PackStrip: 7200.00 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated January 8, 2025.

Compare

Same generic, same strength

Sorted by price per tablet. Ask your pharmacist before you switch brands.

Acalabrutinib 100 mg tablets

Prices as listed on BestinMeds.

1 brand listed
Calcent (this medicine)1200.00 taka per tablet

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Acalabrutinib guide

Indications

Lymphoma Acalabrutinib is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy This indication is approved under accelerated approval based on overall response rate Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

Dosage and administration

The recommended dose is 100 mg orally approximately every 12 hours; swallow whole with water and with or without food. Advise patients not to break, open, or chew capsules. Manage toxicities using treatment interruption, dose reduction, or discontinuation. Avoid Acalabrutinib in patients with severe hepatic impairment.

Side effects

Most common adverse reactions (incidence ≥30%) were: anemia, neutropenia, upper respiratory tract infection, thrombocytopenia, headache, diarrhea, and musculoskeletal pain.

Precautions and warnings

Serious and Opportunistic Infections: Monitor for signs and symptoms of infection and treat promptly Hemorrhage: Monitor for bleeding and manage appropriately Cytopenias: Monitor complete blood counts regularly Second Primary Malignancies: Other malignancies have occurred, including skin cancers and other solid tumors. Advise patients to use sun protection Atrial Fibrillation and Flutter: Monitor for symptoms of arrhythmias and manage

Pregnancy and lactation

Based on findings in animals, Acalabrutinib may cause fetal harm and dystocia when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk. No data are available regarding the presence of Acalabrutinib or its active metabolite in human milk, its effects on the breastfed child, or on milk production.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250